NCT02890355 2026-05-20FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic CancerNational Cancer Institute (NCI)Phase 2 Completed123 enrolled 15 charts